Rudolf Bär adds UK head to STADA roles as Roger Scarlett-Smith retires
The retiring Roger Scarlett-Smith is to be replaced as head of UK at Germany’s STADA Arzneimittel (SAZ: Xetra) by Rudolf Bär.
Mr Bär has assumed responsibility for STADA’s UK operations in addition to his current responsibilities as cluster head and vice-president for mid-sized European markets.
He joined STADA in February 2019 in that role after more than 20 years’ experience in the pharmaceutical industry, including in consumer healthcare, specialty and generics. His prior experience includes a period as head of central Eastern Europe, Middle East and Africa at PGT, the joint venture between Procter and Gamble (NYSE: PG) and Teva Pharmaceutical Industries (NYSE: TEVA).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze